Physician profile
Scott K Nelson
NPI 1144225988
$2,281.17
in general payments reported to CMS, 2019-2025
13 companies · $489 in 2025
The $489 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $177 · 2020: $89.20 · 2021: $312 · 2022: $422 · 2023: $292 · 2024: $499 · 2025: $489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,280.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,280.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $936.66 | 2019-2025 | Clareon, Hydrus Microstent |
| Johnson & Johnson Surgical Vision, INC. | $554.40 | 2023-2025 | Veritas Vision System, Tecnis Simplicity, Tecnis Iol |
| Ocular Therapeutix, INC. | $170.89 | 2022-2025 | Dextenza |
| Biotissue Holdings INC. | $155.58 | 2025 | |
| Rxsight INC | $135.83 | 2022 | |
| Kala Pharmaceuticals, INC. | $71.50 | 2021-2022 | |
| Aerie Pharmaceuticals, INC. | $69.45 | 2020-2021 | |
| Rayner Intraocular Lenses Limited | $69.38 | 2023-2024 | Omidria, Rayone Aspheric, Rayone Emv |
| Sun Pharmaceutical Industries INC. | $34.39 | 2023 | Cequa |
| Allergan, INC. | $29.56 | 2021 | |
| Abbvie INC. | $28.75 | 2023 | |
| Vyera Pharmaceuticals, LLC | $13.76 | 2020 | |
| Novartis Pharmaceuticals Corporation | $11.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.